Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
| ▸ | STS | P08842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14787806 | 0.81 | HTR2C (0.39) | HTR2AHTR2C | |
| SCHEMBL16790852 | 0.75 | CMA1 (0.37) | HTR2AHTR2C | |
| SCHEMBL22143862 | 0.70 | HTR2A (0.37) | HTR2AHTR2C | |
| SCHEMBL1660824 | 0.69 | DRD2 (0.50) | DRD2HTR1ACYP19A1 | |
| SCHEMBL19661160 | 0.69 | DRD2 (0.50) | DRD2HTR1ACYP19A1 | |
| Hydrochloric Acid SCHEMBL6968206 | 0.68 | SLC6A4 (0.44) | HTR2AHTR2CHTR1A | |
| SCHEMBL24628566 | 0.68 | HRH3 (0.35) | HTR2AHTR2C | |
| SCHEMBL22144030 | 0.67 | HTR2A (0.37) | HTR2AHTR2C | |
| SCHEMBL19965486 | 0.67 | HTR2A (0.30) | HTR2AHTR2C | |
| SCHEMBL14625576 | 0.65 | HTR2C (0.64) | HTR2AHTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863136-B1 | Derivatives of azetidine and pyrrolidine | AKZO NOBEL NV (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-6403573-B1 | BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES | AKZO NOBEL N.V. (NL) | 2002-06-11 | — | — | US | disclosed |
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | MERCK SHARP & DOHME B.V. (NL) | 2002-04-04 | — | — | US | disclosed |
| US-6281243-B1 | ANTIDEPRESSANTS, ANTISEROTONINE AGENT | AKZO NOBEL N.V. (NL) | 2001-08-28 | — | — | US | disclosed |
| WO-1999043647-A1 | DERIVATIVES OF AZETIDINE AND PYRROLIDINE | AKZO NOBEL N.V. (NL) | 1999-09-02 | — | — | WO | disclosed |
| EP-0863136-A1 | Derivatives of azetidine and pyrrolidine | Akzo Nobel N.V. (NL) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | TPH1, TPH2, HTR1D | HTR2A 11/4885HTR2C 7/4885DRD2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.